• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Gloria Oliver Rodriguez

2016-04-27News

What is your current role in EPAD?

I am a member of the Legal & IP (intellectual property) Committee (LIPC), representing Barcelonaβeta Brain Research Centre (BBRC) that is co-leading the project and provides the Iberian Lead and a Trial Delivery Centre. The LIPC is composed of six members who are experts in legal, business, or intellectual property matters. We participate in regular discussions by conference calls, and at least once a year we meet face-to-face preferably during the General Assembly Meeting. Our mission is to assist the Steering Committee and the General Assembly in ensuring the correct application of IP ownership and access right clauses in relation to the Associated Trial Delivery Centres, Associated Scientific Collaborators, and Accession of new Participants to the Agreement, and other potential areas where legal or intellectual property advice is useful.

What did you do prior to joining EPAD?

I am part of the BBRC team from its very beginning, assuming the Managing Director Role. I am responsible for directing and controlling the institution’s operations as well as giving strategic guidance and direction to the General Director and the Board to ensure that the BBRC achieves its mission and objectives. To highlight some of my annual functions I would mention that I am responsible of preparing, gaining acceptance, and monitoring the implementation of the yearly budget to ensure its targets are met. In addition, I also lead the processes to develop and maintain an effective marketing and public relations strategy to promote fundraising opportunities.

Tell us a bit about the institution / company / organisation you work for

The Pasqual Maragall Foundation (PMF) for research in Alzheimer’s disease (AD) was established in April 2008, as the result of the public engagement of Pasqual Maragall, former mayor of Barcelona and president of the Government of Catalonia, when he announced he had been diagnosed with the disease. The PMF is affiliated to the Pompeu Fabra University in Barcelona (UPF) and develops its research in a joint center venture with UPF, the Barcelonaβeta Brain Research Center (BBRC).

BBRC addresses the challenges AD poses from a scientific point of view, with the decisive commitment to provide solutions and improve the welfare of persons affected by the disease. Its activity is directed at obtaining new scientific knowledge with the objectives of reducing the number of patients, delaying disease progression and providing solutions that improve the quality of life of both patients and their caregivers.

We also campaign to improve public understanding of AD and the devastating impact it can have, and make sure it is taken seriously and acted on by our governments.

Finally, the Foundation through its research centre, BBRC, is conducting the ALFA project for the prospective follow-up of a cohort of cognitively normal participants, many of them first-degree descendent of AD patients, with the aim of increasing our knowledge of the pathophysiology and pathogenic factors emerging at early preclinical AD stages. Within this project, the ALFA parent cohort is composed of 2743 cognitively healthy participants representing the whole spectrum of risk of developing AD that will leverage with different projects. One of these, the longitudinal ALFA+ cohort study will serve, through deep phenotyping, to untangle the natural history of the disease and to model its earliest stages to develop successful trials. Our most ambitious aim is to follow ALFA study participants throughout their lives.

BBRC is working for a future without AD: nowhere is it written that it is invincible.

What are your expectations from the EPAD project?

It is becoming increasingly more evident that many of the changes in the brain that lead to AD dementia start decades before symptoms appear. We therefore need to know how to identify these changes in middle-aged persons and also work out how we can intervene to stop them from progressing. We may be able to stop progression through specific pharmacological and non-pharmacological interventions.

My expectations are,

  1. To have an extensive pan-European cohort of persons at risk of developing Alzheimer’s dementia that will provide an extraordinary opportunity to better understand human biology behavior and compile enough information about risk factors to develop AD. Hopefully, this will allow us to,
  1. Find a treatment capable of preventing or delaying the evolution of the disease and the appearance of AD dementia.
  1. Finally, BBRC involvement in the EPAD project together with leading experts in the AD prevention research field, will enable collaborations between us and other groups similarly determined to fight against AD.
Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Analysis of multiple steroids in saliva in the EPAD study
2023-03-02
Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
2023-01-16
Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
2022-12-09
Bruno Steinkraus
Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
2022-11-25
New paper defining and discussing the substantial assets of the EPAD project is out!
2022-11-23
New paper using the EPAD data for an analysis of sleep quality and efficiency
2022-11-03
Latest News
  • Analysis of multiple steroids in saliva in the EPAD study
    2023-03-02
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
  • Bruno Steinkraus
    Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
    2022-11-25
  • New paper defining and discussing the substantial assets of the EPAD project is out!
    2022-11-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

📢@imi_epnd has launched its Cohort Catalogue, a central, open & accessible repository for researchers to discover studies & search metadata. Currently 67 research cohorts from 17 countries across Europe including @IMI_EPAD-VUmc participants ⬇️ eurekalert.org/news-releases/… twitter.com/imi_epnd/statu…

reply retweet favorite
9:56 am · 2023-03-14
Twitter
EPAD
EPAD
@IMI_EPAD

NEW paper published in @MetabolitesMDPI using LC-MS/MS method to determine salivary steroids using @IMI_EPAD samples. Congratulations @GregorySarah @zinghomer @guider50 @scottgdenham👏 @EdMassSpecCore @IMI2_NEURONET @IHIEurope #mdpimetabolites mdpi.com/2133518

reply retweet favorite
12:55 pm · 2023-03-02
Twitter
EPAD
EPAD
@IMI_EPAD

"There is a growing consensus that individual research results that are potentially relevant should be reported to research participants” & “Our work was positively received by the EPAD partners, and formed the basis for the set-up & the conduct of the study,” said Eline Bunnik

reply retweet favorite
10:32 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @IHIEurope newsletter including a spotlight on IMI results from projects on diabetes @HypoResolve and #Alzheimer’s disease @IMI_EPAD @IMI_AMYPAD ⬇️ Read it: bit.ly/3jeaxdM twitter.com/IHIEurope/stat…

reply retweet favorite
10:30 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

17 centres have contributed to the @IMI_AMYPAD Prognostic Study across 11 Parent Cohorts including @IMI_EPAD. Have a look on the latest AMYPAD paper published in @FrontNeurol ⬇️ twitter.com/IMI_AMYPAD/sta…

reply retweet favorite
8:19 am · 2023-01-30
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Analysis of multiple steroids in saliva in the EPAD study
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
  • Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
  • New paper defining and discussing the substantial assets of the EPAD project is out!
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT